Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/1999
09/30/1999WO1999048894A1 Novel cephalotaxane derivatives and process for their preparation
09/30/1999WO1999048892A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors
09/30/1999WO1999048891A1 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as nmda receptor antagonists
09/30/1999WO1999048889A1 Halimide, a cytotoxic marine natural product, and derivatives thereof
09/30/1999WO1999048888A1 Imidazolone anorectic agents: ii. phenyl derivatives
09/30/1999WO1999048887A1 Imidazolone anorectic agents: iii. heteroaryl derivatives
09/30/1999WO1999048881A1 Metalloproteinase inhibitors
09/30/1999WO1999048879A1 Thiocarboxamide derivatives and their use as inhibitors of alpha-4 integrins
09/30/1999WO1999048878A1 Heterocyclic compounds regulating clotting
09/30/1999WO1999048873A1 Imidazolone anorectic agents: i. acyclic derivatives
09/30/1999WO1999048871A1 Pyridine derivative and pharmaceutical containing the same
09/30/1999WO1999048870A1 Piperididinyl and n-amidinopiperidinyl derivatives
09/30/1999WO1999048868A2 Heterocyclic classes of compounds for the modulating tyrosine protein kinase
09/30/1999WO1999048865A1 New compounds
09/30/1999WO1999048860A1 Anti-tumour agents
09/30/1999WO1999048859A1 Aryloxyanilides and related compounds
09/30/1999WO1999048858A2 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents
09/30/1999WO1999048857A1 Anti-tumour agents
09/30/1999WO1999048531A1 Remedies for hepatitis
09/30/1999WO1999048530A1 Combination therapy for the treatment of benign prostatic hyperplasia
09/30/1999WO1999048529A1 Retinoid-glitazone combinations
09/30/1999WO1999048523A2 Antagonists of the inflammatory mediator oncostatin m (osm)
09/30/1999WO1999048522A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment
09/30/1999WO1999048514A1 Methods and materials for treating inflammatory diseases
09/30/1999WO1999048507A2 Steroidal saponins for treating alzheimer's disease
09/30/1999WO1999048503A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
09/30/1999WO1999048502A1 USE OF 17β-ESTRADIOL, ANALOGS AND DERIVATIVES THEREOF FOR THE TREATMENT OF DIABETES MELLITUS AND ITS MANIFESTATIONS
09/30/1999WO1999048501A1 Voacamine as anti-malarial agent and anti-malarial agent containing voacamine
09/30/1999WO1999048500A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
09/30/1999WO1999048499A1 Paroxetine compositions
09/30/1999WO1999048498A1 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
09/30/1999WO1999048497A1 USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE
09/30/1999WO1999048496A1 Therapy of estrogen-associated disorders
09/30/1999WO1999048495A1 Benzoates derivatives for inhibiting angiogenesis
09/30/1999WO1999048494A1 Sustained-release composition of oxybutynin with reduced xerostomia effect
09/30/1999WO1999048493A1 Transdermal therapeutic system (tts) containing oxybutynin
09/30/1999WO1999048492A1 Amide derivatives and nociceptin antagonists
09/30/1999WO1999048491A1 NF-λB INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE
09/30/1999WO1999048490A1 Allosteric inhibitors and activators of pyruvate kinase
09/30/1999WO1999048489A2 Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
09/30/1999WO1999048488A2 Methods for decreasing beta amyloid protein
09/30/1999WO1999048487A1 Multi-carotenoid product
09/30/1999WO1999048485A1 Method of treating neuroma pain
09/30/1999WO1999048484A2 Use of cabergoline in the treatment of restless legs syndrome
09/30/1999WO1999048483A2 (-)-phenylpropanolamine as a sympathomimetic drug
09/30/1999WO1999048482A2 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
09/30/1999WO1999048477A1 Topical hormonal composition with systemic effect
09/30/1999WO1999048476A1 Improved compositions for inhalation
09/30/1999WO1999048475A1 Improved crystal structure
09/30/1999WO1999048471A1 Polyalkoxy copolymers as lipase inhibitors and their compositions
09/30/1999WO1999048468A1 Method for accelerated administration of carotenoid mixtures in serum and tissues
09/30/1999WO1999048461A2 Substituted aromatic compounds for treatment of antibiotic resistant infections
09/30/1999WO1999048361A1 Xylitol compositions for treating upper respiratory conditions
09/30/1999WO1999042465A3 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
09/30/1999WO1999042134A3 Spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin and a method of making such spray-dried tablettable powders
09/30/1999WO1999040904A3 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
09/30/1999WO1999039741A3 Systemic delivery of serum stable plasmid lipid particles for cancer therapy
09/30/1999WO1999038877A3 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
09/30/1999WO1999038532A3 Methods for the prevention and treatment of fibrosis and sclerosis
09/30/1999WO1999038518A3 Synergistic mixtures of garlic and lycopene for preventing ldl oxidation
09/30/1999WO1999038506A3 Use of topical preparations of glyceryl trinitrate and lanolin for the treatment of erectile dysfunction
09/30/1999WO1999038499A3 Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
09/30/1999WO1999037788A3 Diagnosis and treatment of aur1 and/or aur2 related disorders
09/30/1999WO1999037167A3 Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby
09/30/1999WO1999036562A9 Nucleotide expression systems with reduced immunogenicity for use in gene therapy
09/30/1999WO1999036410A9 Triazine antiviral compounds
09/30/1999WO1999035277A3 Recombinant, active caspases and uses thereof
09/30/1999WO1999035266A3 Human urotensin ii
09/30/1999WO1999035246A9 Novel steroid-activated nuclear receptors and uses therefor
09/30/1999WO1999034808B1 Use of extracts of geraniine geranium or related compounds for preparing analgesic medicines of central non-morphine type
09/30/1999WO1999033853A3 Carbohydrates, useful in solid delivery systems
09/30/1999WO1999032449A3 Benzazine derivatives as phosphodiesterase 4 inhibitors
09/30/1999WO1999031122A9 Antipicornaviral compounds and methods for their use and preparation
09/30/1999WO1999029308A3 Method for combating obesity
09/30/1999WO1999010321A3 Antimicrobial compounds
09/30/1999WO1999006340A3 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
09/30/1999DE19913864A1 DNA fragments useful for increasing p53 activity in a cell and reducing susceptibility to UV-induced hyperproliferative diseases
09/30/1999DE19861012A1 Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease
09/30/1999DE19813773A1 Verfahren zur Herstellung von liposomalen Wirkstoffformulierungen Process for the preparation of liposomal drug formulations
09/30/1999CA2325943A1 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents
09/30/1999CA2325935A1 Heterocyclic families of compounds for the modulation of tyrosine protein kinase
09/30/1999CA2325879A1 Voacamine as anti-malarial agent and anti-malarial agent containing voacamine
09/30/1999CA2325689A1 Substituted aromatic compounds for treatment of antibiotic resistant infections
09/30/1999CA2325638A1 Amide derivatives and nociceptin antagonists
09/30/1999CA2325634A1 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
09/30/1999CA2325631A1 Therapy of estrogen-associated disorders
09/30/1999CA2325588A1 Imidazolone anorectic agents: i. acyclic derivatives
09/30/1999CA2325587A1 Imidazolone anorectic agents: ii. phenyl derivatives
09/30/1999CA2325585A1 Inflammatory mediator antagonists
09/30/1999CA2325584A1 Improved compositions for inhalation
09/30/1999CA2325551A1 Improved crystal structure
09/30/1999CA2325550A1 Remedies for hepatitis
09/30/1999CA2325472A1 Imidazolone anorectic agents: iii. heteroaryl derivatives
09/30/1999CA2325460A1 Azt derivatives exhibiting spermicidal and anti-viral activity
09/30/1999CA2325417A1 Halimide, a cytotoxic marine natural product, and derivatives thereof
09/30/1999CA2325396A1 Sucrose-n-alkyl-asparaginates, production and use thereof
09/30/1999CA2324999A1 Methods for decreasing .beta.-amyloid protein
09/30/1999CA2324895A1 Novel cephalotaxane derivatives and process for their preparation
09/30/1999CA2324612A1 Paroxetine compositions
09/30/1999CA2324610A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate